Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RO7568282 in early Parkinson's disease
CTR20263567Phase 2Active
- Sponsor
- Roche
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RO7568282 in Parkinson's disease (PD), sponsored by Roche. Started Sep 2026; status: active.
02
Drugs
RO7568282
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20263567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263567.